GGrantIndex
← Leaderboards

Joy Melnikow

University Of California Davis

$3,604,743
Attributed
$3,604,743
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $460.8K · FY200518
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

AHRQ$2,060,113 · 1
NIH$1,394,630 · 2
CDC$150,000 · 1

By mechanism

T32$2,060,113 · 1
R01$1,394,630 · 2
U58$150,000 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of California Davis

Same institution · by research overlap

Others in their field

Top investigators on “Cost Effectiveness

Research focus

Cost EffectivenessPreferenceClinical ResearchBreast NeoplasmsFemaleBehavioral /Social Science Research TagHuman SubjectTamoxifenChemopreventionCancer PreventionWomen'S HealthCodeCervicalCohortDeveloping CountriesClassificationBaseData SetCytologyCost Effectiveness AnalysisCessation Of LifeDeveloped CountriesCostCervical Intraepithelial Neoplasia

Grant awards (16)

Quality Safety Comparative Effectiveness Research Training (QSCERT)$164,411
T32 · FY2018 · HS · contact PI
Quality Safety Comparative Effectiveness Research Training (QSCERT)$421,896
T32 · FY2017 · HS · contact PI
Quality Safety Comparative Effectiveness Research Training (QSCERT)$5,357
T32 · FY2017 · HS · contact PI
Quality Safety Comparative Effectiveness Research Training (QSCERT)$460,780
T32 · FY2016 · HS · contact PI
Quality Safety Comparative Effectiveness Research Training (QSCERT)$398,413
T32 · FY2015 · HS · contact PI
Quality Safety Comparative Effectiveness Research Training (QSCERT)$389,664
T32 · FY2014 · HS · contact PI
Quality Safety Comparative Effectiveness Research Training (QSCERT)$219,592
T32 · FY2013 · HS · contact PI
CD11-1102, Promoting Health Policy and Disease Prevention$150,000
U58 · FY2011 · CD · contact PI
Surveillance Strategies Following Treatment for CIN$139,162
R01 · FY2007 · CA · contact PI
Surveillance Strategies Following Treatment for CIN$342,172
R01 · FY2006 · CA · contact PI
Surveillance Strategies Following Treatment for CIN$296,749
R01 · FY2005 · CA
TAMOXIFEN &BREAST CANCER--ACCEPTANCE/COST EFFECTIVENESS$267,075
R01 · FY2002 · CA
TAMOXIFEN &BREAST CANCER--ACCEPTANCE/COST EFFECTIVENESS$18,018
R01 · FY2002 · CA
TAMOXIFEN &BREAST CANCER--ACCEPTANCE/COST EFFECTIVENESS$171,143
R01 · FY2001 · CA
TAMOXIFEN &BREAST CANCER--ACCEPTANCE/COST EFFECTIVENESS$20,938
R01 · FY2001 · CA
TAMOXIFEN &BREAST CANCER--ACCEPTANCE/COST EFFECTIVENESS$139,373
R01 · FY2000 · CA